证券代码：688621 证券简称：阳光诺和 公告编号：2023-068 北京阳光诺和药物研究股份有限公司 关于召开终止重大资产重组投资者说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京阳光诺和药物研究股份有限公司（以下简称"公司""上市公司"）于 2023 年 8 月 25 日分别召开第二届董事会第五次会议、第二届监事会第五次会议， 审议通过了《关于终止发行股份及支付现金购买资产并募集配套资金暨关联交易 事项并撤回申请文件的议案》《关于公司与交易对方签署相关终止协议的议案》， 同意上市公司终止发行股份及支付现金购买资产并募集配套资金暨关联交易事 项并撤回申请文件以及与交易对方签署相关终止协议。具体内容详见上市公司于 2023 年 8 月 26 日 在 指 定 信 息 披 露 媒 体 和 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn）的公告。 为便于广大投资者更全面深入地了解上市公司终止本次重大资产重组交易 事项，上市公司计划于 2023 年 8 月 29 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2023-066 北京阳光诺和药物研究股份有限公司 第二届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"）于2023年8月25 日召开第二届监事会第五次会议。经全体监事一致同意，本次会议已豁免通知期 限，会议通知于2023年8月24日通过口头、电话与邮件等方式送达给全体监事。 会议由监事会主席王丹丹女士召集和主持，会议应出席监事3名，实际出席监事3 名，全部监事均参与表决所有议案。会议的召集和召开符合《中华人民共和国公 司法》及《公司章程》的规定。 二、监事会会议审议情况 经与会监事认真审议，一致通过如下决议： （一）审议通过《关于终止发行股份及支付现金购买资产并募集配套资金暨 关联交易事项并撤回申请文件的议案》 公司监事会认为，公司终止本次发行股份及支付现金购买资产并募集配套资 金事项的审议程序符合有关法律、法规及《公司章程》的规定，不会对公司经营 活动和财务状况造成 ...

北京阳光诺和药物研究股份有限公司独立董事 关于第二届董事会第五次会议审议的相关事项 的事前认可意见 根据中国证监会《上市公司重大资产重组管理办法》《关于在上市公司建立 独立董事制度的指导意见》《上海证券交易所科创板股票上市规则》等法律法规 及《北京阳光诺和药物研究股份有限公司章程》等有关规定，我们作为公司的独 立董事，本着对公司、全体股东负责的态度，基于独立、客观、审慎的原则，现 就公司第二届董事会第五次会议拟审议的相关事项发表如下事前认可意见： 北京阳光诺和药物研究股份有限公司拟通过发行股份及支付现金方式购买 江苏朗研生命科技控股有限公司（原名为"北京朗研生命科技控股有限公司"， 2023 年 7 月 3 日完成注册地址及公司名称变更）100%股权，并向不超过 35 名特 定投资者发行股份募集配套资金（以下统称"本次重组"或"本次交易"）。 朱慧婷 时 现 何壮坤 2023 年 8 月 25 日 经核查，本次重组自启动以来，公司及相关各方积极推动本次重组的实施工 作，并严格按照相关法律法规及规范性文件的要求履行信息披露义务。经公司审 慎研究并与交易对方友好协商后，决定终止本次重组事项，撤回本次重组相关申 请 ...

经与会董事认真审议，一致通过如下决议： （一）审议通过《关于终止发行股份及支付现金购买资产并募集配套资金 暨关联交易事项并撤回申请文件的议案》 公司2023年第一次临时股东大会审议通过公司拟通过发行股份及支付现金 方式购买江苏朗研生命科技控股有限公司（原名为"北京朗研生命科技控股有限 公司"，2023年7月3日完成注册地址及公司名称变更）100%股权，并向不超过 35名特定投资者发行股份募集配套资金（以下统称"本次重组"或"本次交易"）。 证券代码：688621 证券简称：阳光诺和 公告编号：2023-065 北京阳光诺和药物研究股份有限公司 第二届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"）于2023年8月25 日召开第二届董事会第五次会议。经全体董事一致同意，本次会议已豁免通知期 限，会议通知于2023年8月24日通过口头、电话与邮件等方式送达给全体董事。 会议由董事长利虔先生召集和主持，会议应出席董事9名，实际出 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2023-064 北京阳光诺和药物研究股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东基本情况 截止本公告披露日，北京阳光诺和药物研究股份有限公司（以下简称"阳光 诺和"）股东杭州海达明德创业投资合伙企业（有限合伙）（以下简称"海达明德"） 持有公司 1,910,472 股股票，占公司总股本的 1.7058%，宁波海达睿盈创业投资 合伙企业（有限合伙）（以下简称"睿盈投资"）持有公司 1,686,832 股股票，占 公司总股本的 1.5061%，广州正达创业投资合伙企业（有限合伙）（以下简称"广 州正达"）持有公司 1,798,646 股股票，占公司总股本的 1.6059%，杭州汇普直 方股权投资合伙企业（有限合伙）（以下简称"汇普直方"）持有公司 901,927 股 股票，占公司总股本的 0.8053%，宁波海达睿盈股权投资管理有限公司（以下简 称"睿盈管理"）持有公司 49,156 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2023-063 北京阳光诺和药物研究股份有限公司 持股 5%以上股东减持计划时间届满 暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次股份减持计划实施前，北京阳光诺和药物研究股份有限公司（以下简称 "阳光诺和"）股东杭州海达明德创业投资合伙企业（有限合伙）（以下简称"海 达明德"）持有公司 1,567,680 股股票，占公司总股本的 1.9596%，宁波海达睿 盈创业投资合伙企业（有限合伙）（以下简称"睿盈投资"）持有公司 1,396,802 股股票，占公司总股本的 1.7460%，广州正达创业投资合伙企业（有限合伙）（以 下简称"广州正达"）持有公司 1,336,547 股股票，占公司总股本的 1.6707%， 杭州汇普直方股权投资合伙企业（有限合伙）（以下简称"汇普直方"）持有公 司 742,654 股股票，占公司总股本的 0.9283%，宁波海达睿盈股权投资管理有限 公司（以下简称"睿盈管 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2023-043 北京阳光诺和药物研究股份有限公司 关于召开 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京阳光诺和药物研究股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2023 年一季度报告，为便于广大投资者更全面深入地了解公司 2023 年一季度经营成果、财务状况，公司计划于 2023 年 06 月 05 日上午 10:00-11:00 举行 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年一季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2023 年 06 月 05 日(星期一)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥232,434,204.44, representing a year-on-year increase of 57.09%[5] - The net profit attributable to shareholders was ¥47,937,215.67, reflecting a growth of 43.52% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥47,020,028.14, which is an increase of 50.81% year-on-year[5] - The basic earnings per share for the period was ¥0.60, up by 42.86% from the previous year[6] - Operating profit for Q1 2023 was ¥52,472,219.95, up 36.0% from ¥38,542,580.67 in Q1 2022[18] - Net profit attributable to shareholders for Q1 2023 was ¥47,937,215.67, representing a 43.5% increase from ¥33,400,168.75 in Q1 2022[19] - Basic and diluted earnings per share for Q1 2023 were both ¥0.60, compared to ¥0.42 in Q1 2022, reflecting a 42.9% increase[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,498,573,270.73, a 2.42% increase from the end of the previous year[6] - Total current assets increased to ¥1,048,177,587.18 from ¥1,039,962,682.05, a rise of approximately 0.1%[14] - Non-current assets totaled ¥450,395,683.55, up from ¥423,131,101.05, indicating a growth of about 6.4%[15] - Total liabilities decreased to ¥542,442,511.54 in Q1 2023 from ¥554,861,860.83 in Q1 2022, a reduction of approximately 2.0%[16] - Total equity increased to ¥956,130,759.19 in Q1 2023 from ¥908,231,922.27 in Q1 2022, marking a growth of about 5.3%[16] Cash Flow - The cash flow from operating activities was negative at -¥83,204,600.77, indicating challenges in cash generation during the period[5] - Cash flow from operating activities in Q1 2023 was ¥87,665,129.29, down from ¥120,674,024.00 in Q1 2022, a decrease of 27.4%[19] - The net cash flow from operating activities was -$83.20 million, a significant decline compared to $3.35 million in the previous year, indicating a negative trend in operational cash generation[21] - The total cash outflow from operating activities was $170.87 million, compared to $117.33 million in the previous year, indicating increased operational expenses[21] - The ending cash and cash equivalents balance decreased to $502.01 million from $581.53 million, reflecting a decline in liquidity[22] Research and Development - Research and development expenses totaled ¥19,334,882.12, accounting for 8.32% of operating revenue, which is a decrease of 3.03 percentage points[6] - Research and development expenses for Q1 2023 were ¥19,334,882.12, an increase of 15.5% compared to ¥16,792,661.77 in Q1 2022[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 3,491[11] - The largest shareholder, Li Du, holds 22,069,500 shares, representing 27.59% of total shares[11] - The number of shares pledged by Liu Yujing is 2,000,000, indicating a potential risk factor for investors[11] Investment Activities - Total cash inflow from investing activities was $3.16 million, down from $109.17 million year-over-year, reflecting reduced investment recovery[21] - The net cash flow from investing activities was -$54.59 million, contrasting sharply with a positive $69.92 million in the same quarter last year, highlighting a shift in investment strategy[21] - Cash paid for investments was $26.00 million, significantly higher than $4.00 million in the previous year, showing increased capital expenditure[21] Financial Management - Cash inflow from financing activities increased to $72.00 million, compared to $29.00 million in the previous year, indicating a stronger reliance on external financing[21] - The net cash flow from financing activities was $30.88 million, up from $18.01 million year-over-year, suggesting improved capital management[21] - The company reported a credit impairment loss of ¥10,212,529.96 in Q1 2023, compared to a loss of ¥4,218,839.88 in Q1 2022[18] Accounting Standards - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[22]

Financial Performance - In 2022, the company achieved a total revenue of 676.61 million yuan and a net profit attributable to shareholders of 155.95 million yuan, resulting in an earnings per share of 1.95 yuan[4]. - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-over-year increase of 15%[22]. - The company achieved operating revenue of CNY 676.61 million in 2022, representing a year-on-year growth of 37.06%[30]. - Net profit attributable to shareholders reached CNY 155.95 million, up 47.59% compared to the previous year[30]. - The net profit after deducting non-recurring gains and losses was CNY 141.63 million, reflecting a growth of 38.69% year-on-year[30]. - The net cash flow from operating activities was CNY 103.96 million, an increase of 17.80% from the previous year[32]. - The company's total assets at the end of 2022 amounted to CNY 1,463.09 million, a growth of 17.74% compared to the end of 2021[33]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization efforts[22]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q3 2023, representing a 20% year-over-year growth[193]. Research and Development - The R&D investment for 2022 was 89.69 million yuan, accounting for 13.26% of total revenue, with a dedicated R&D team of 951 personnel, representing 84.46% of the workforce[7]. - Research and development expenses increased to RMB 300 million, accounting for 25% of total revenue, reflecting the company's commitment to innovation[22]. - The R&D investment accounted for 13.26% of operating revenue, an increase of 3.62 percentage points from the previous year[31]. - The company has established partnerships with three leading CROs to enhance its research capabilities and expedite drug development[22]. - The company has invested in new technology platforms to enhance R&D capabilities, which has led to stable growth in market orders[44]. - The company is focusing on the development of innovative drugs, particularly peptide and small nucleic acid drugs, with all research projects being self-initiated[50]. - The company has accumulated 154 intellectual property rights, including 36 granted invention patents, reflecting its commitment to innovation[71]. - The company is focusing on developing specialized services in hot research areas, such as oncology, to differentiate itself in the market[68]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[22]. - The company aims to launch three new products in 2023, which are projected to contribute an additional RMB 200 million in revenue[22]. - The company is actively pursuing market expansion strategies, targeting public hospitals and community health centers across China[90]. - Market expansion plans include entering three new regions, aiming for a 15% market share in these areas within the next two years[190]. - The company is considering strategic acquisitions to enhance its product portfolio, with a focus on companies that align with its core competencies[190]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[199]. Client and Order Growth - The company served over 650 clients and secured new orders amounting to 1.102 billion yuan, with total backlog orders also reaching 1.102 billion yuan[4]. - The company signed new orders worth CNY 1.102 billion in 2022, marking an 18.62% increase year-on-year[32]. - The company has established a strong market position in the CRO sector, providing comprehensive drug R&D services to over 650 clients, with 155 new clients added during the reporting period[46]. Product Development and Innovation - Eight new drug projects received NMPA approval to enter clinical trials, and 60 drug applications were accepted for market registration[5]. - The company has completed two strategic acquisitions in the past year, enhancing its product portfolio and market capabilities[22]. - The company has initiated clinical research for a third-class medical device and multiple new drug clinical studies, indicating active engagement in innovative drug development[52]. - The company is focusing on the development of new formulations with improved stability and bioequivalence, which are essential for market competitiveness[86]. - The company has completed the registration of multiple new drugs, including a chemical generic drug classified as Category 4, which is currently under strict control for process parameters[84]. Risk Management - The company has outlined potential risks in its annual report, emphasizing the importance of risk management in its operations[9]. - The company faces risks related to rapid technological advancements in the CRO industry, which may require continuous investment in new technologies and talent to maintain competitiveness[108]. - The company acknowledges the inherent risks in drug development, including potential failures due to various internal and external factors, which could impact profitability and contract obligations[108]. Governance and Management - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, including various committees such as the strategy and audit committees[180]. - The company has a clear mechanism for the separation of powers among its governance bodies, ensuring effective checks and balances[180]. - The company has maintained a consistent leadership structure with executives holding multiple roles across various firms, enhancing its influence in the market[197]. Sustainability Initiatives - The management team emphasized a commitment to sustainability, with plans to implement eco-friendly practices across all operations by 2025[198]. - The company is committed to sustainability initiatives, aiming to reduce its carbon footprint by 20% by 2025[190].

证券代码：688621 证券简称：阳光诺和 公告编号：2023-020 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 03 月 23 日上午 10:00-11:00 会议召开时间：2023 年 03 月 23 日(星期四)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 16 日(星期四)至 03 月 22 日(星期三)16:00 前登录 上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 ir@sun-novo.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 北京阳光诺和药物研究股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在 ...